SI-BONE, Inc. director Jeffrey W. Dunn filed a Form 4 on September 3, 2026, reporting stock option exercises and open-market sales of common stock that occurred on September 1, 2026, pursuant to a pre-established 10b5-1 trading plan.

Key Highlights

  • Options exercised: Dunn exercised stock options in two tranches: 18,633 shares at an exercise price of $4.68 and 1,367 shares at an exercise price of $4.68, totaling 20,000 shares of common stock acquired via code-M transactions.
  • Shares sold: Dunn sold 18,633 shares and then 1,367 shares on September 1, 2026, at a weighted-average price of $18.908 per share, with individual transactions ranging from $18.6450 to $19.6449.
  • Direct ownership after transactions: Following the reported transactions, Dunn directly held 16,057 shares of common stock, including 10,957 shares issuable on settlement of restricted stock units.
  • Indirect ownership: Dunn also held 81,073 shares indirectly through The Jeffrey W. Dunn Living Trust Dated May 17, 2012.
  • 10b5-1 plan: According to the filing, the sales were effected pursuant to a 10b5-1 trading plan dated May 7, 2025.
  • Remaining options: After the exercise, Dunn retained 104,893 stock options (following the 1,367-share exercise) and 86,260 options (following the 18,633-share exercise), both carrying an exercise price of $4.68 and expiring March 1, 2027.

SI-BONE Director Discloses Option Exercises and Sales Under Pre-Planned Trading Program

According to the Form 4 filed with the SEC on September 3, 2026, Jeffrey W. Dunn, a director of SI-BONE, Inc. (NASDAQ:SIBN), a Santa Clara, California-based company, executed two stock option exercises on September 1, 2026. The filing shows Dunn acquired 18,633 shares and 1,367 shares of common stock under code-M transactions, both at the option exercise price of $4.68 per share.

On the same date, the filing reports that Dunn disposed of those shares through two corresponding sale transactions: 18,633 shares and 1,367 shares, each at a weighted-average price of $18.908 per share. The filing states the shares were sold in multiple transactions ranging from $18.6450 to $19.6449 per share, inclusive, and that Dunn will provide full per-price transaction detail upon request to the issuer, any securityholder, or SEC staff. Both sales were conducted under a Rule 10b5-1 trading plan dated May 7, 2025, as disclosed in the filing's explanation of responses.

Following all reported transactions, the filing indicates Dunn directly holds 16,057 shares of common stock. That figure includes 10,957 shares issuable upon settlement of restricted stock units, each representing a contingent right to receive one share of SI-BONE common stock. In addition, Dunn holds 81,073 shares indirectly through The Jeffrey W. Dunn Living Trust Dated May 17, 2012. The filing was signed by Michael A. Pisetsky as attorney-in-fact for Jeffrey W. Dunn on September 3, 2026.

What Was Disclosed

The filing reports director Jeffrey W. Dunn's exercise of stock options covering 20,000 shares of SI-BONE common stock and the subsequent sale of those shares on September 1, 2026, under a pre-established 10b5-1 trading plan, along with his resulting direct and indirect beneficial ownership positions.